CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $34,252
- in 1 filing
Net −$34,252. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-09-13 | Capone Mark Christopher President & C.E.O. | Grant or award | +165,000 | 372,451 | ||
| 2017-09-13 | LANCHBURY JERRY S Chief Scientific Officer | Grant or award | +50,000 | 157,034 | ||
| 2017-09-13 | MARSH RICHARD M E.V.P., General Counsel | Grant or award | +50,000 | 155,729 | ||
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $16.46 | $165K | 52,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Sale | −10,000 | $30.31 | $303K | 42,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $16.46 | $165K | 52,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Sale | −10,000 | $30.30 | $303K | 42,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $16.46 | $165K | 52,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Sale | −10,000 | $30.30 | $303K | 42,524 |
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 20,000 | ||
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 10,000 | ||
| 2017-09-01 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 0 | ||
| 2017-02-23 | HENDERSON JOHN T Director | Purchase | +3,600 | $18.58 | $67K | 42,124 |
| 2017-02-23 | HENDERSON JOHN T Director | Purchase | +400 | $18.57 | $7K | 42,524 |
| 2017-02-22 | HENDERSON JOHN T Director | Purchase | +2,000 | $18.81 | $38K | 38,524 |
| 2017-01-03 | Tobin Bernard President Crescendo BioScience | Returned to the company | −2,631 | $16.93 | $45K | 116,360 |
| 2016-12-01 | Phanstiel S. Louise Director | Grant or award | +15,024 | 23,524 | ||
| 2016-12-01 | DREISMANN HEINRICH Director | Grant or award | +15,024 | 32,524 | ||
| 2016-12-01 | LANGER DENNIS Director | Grant or award | +15,024 | 32,524 | ||
| 2016-12-01 | GILBERT WALTER PHD Director | Grant or award | +15,024 | 27,524 |
Page 47 of 60 · 1,194 trades